Articles On Genetic Signatures (ASX:GSS)

Title Source Codes Date
Buy this small cap ASX stock with a 'lucrative opportunity'

Now could be the time to pounce on one small cap ASX stock if your risk tolerance allows for it. That's the view of analysts at Bell Potter, which believe this speculative stock could have a "lucrative opportunity" in the United States. Whi...

Motley Fool GSS 1 week ago
ASX Health June Winners: Actinogen and Optiscan led a sector in good shape

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Stockhead GSS 2 weeks ago
The ASX biotechs with secured FDA clearances in 2024, and others looking likely

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

Stockhead GSS 3 weeks ago
Genetic Signatures secures FDA clearance for gastrointestinal parasite detection kit

Molecular diagnostics company Genetic Signatures (ASX:GSS) has announced that the US FDA has cleared its EasyScreen Gastrointestinal Parasite Detection Kit and GS1 automated workflow for marketing and sale in the US.

BiotechDispatch GSS 1 month ago
Closing Bell: Aussie shares slip on commodities dip; but Goldies soar on rates hopes

Aussie shares down on weaker commodities Iron ore and energy stocks slip, while goldies gain Intel CEO Pat Gelsingers takes swipe at Nvidia’s CEO Jensen Huang   Aussie shares dropped slightly on Tuesday, closing -0.2% lower as the impact...

Stockhead GSS 1 month ago
Guess which ASX gold stock crashed over 20% today

It was a tough start to the week for the St Barbara Ltd (ASX: SBM) share price. The ASX gold stock was down as much as 21% to 22 cents before eventually closing the session at 23.5 cents. Why did this ASX gold stock crash? Investors were hi...

Motley Fool GSS 1 month ago
Closing Bell: Rare earths hit launches 300pc small cap moon shot as ASX benchmark beards its bears

ASX in broad rebound; Cettire, Neuren, and Lendlease lead surge Positive sentiment follows Wall Street strength DY6 Metals up 300pc on  Rare Earths find at the Tundulu project in Malawi   Aussie shares rebounded pretty much across the boa...

Stockhead GSS 1 month ago
Why inflation could cost young investors 50% of their retirement savings

By now, all Australians would be aware of the woes that high inflation has brought upon us. After virtually disappearing as an economic concern for a decade, the post-pandemic era saw inflation rear its ugly head once more. This could have...

Motley Fool GSS 1 month ago
Why Genetic Signatures, Retail Food Group, Smartpay, and St Barbara shares are tumbling today

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a decent gain. At the time of writing, the benchmark index is up 0.75% to 7,784.4 points. Four ASX shares that have failed to follow the market higher today a...

Motley Fool GSS 1 month ago
ASX Health Stocks: EMV’s AI algo shows promise, and Telix submits new FDA application

EMVision’s AI algorithm shows promise EMvision Medical Devices (ASX:EMV) has shared an update from its ongoing clinical trials focusing on improving EMVision’s AI algorithms for diagnosing strokes caused by bleeding or blockages in the brai...

Stockhead GSS 1 month ago
Should I buy ASX shares now, or wait for a stock market crash?

Stock market crashes can cause a lot of pain when they do occasionally occur. When a crash happens, there's widespread and indiscriminate selling by fearful investors. While living through a bear market is unsettling, it can also often...

Motley Fool GSS 1 month ago
Check Up: Alzheimer’s is ‘preventable’, so here’s what you must do; and recent ASX biotech winners

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Stockhead GSS 1 month ago
ASX Health Winners April: Mesoblast leads; and why the Health sector is just built different

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

Stockhead GSS 2 months ago
Check Up: Big breakthrough in acne treatment, and recent ASX biotech winners

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

Stockhead GSS 2 months ago
Closing Bell: A big relief rally for the ASX today; copper continues its bull market rally

The ASX staged a relief rally on Monday Gold, oil stocks struggled after tensions in the Middle East eased The focus has now shifted from Middle East tensions to company earnings   The ASX put on a relief rally after its -3% loss last wee...

Stockhead GSS 2 months ago
Genetic Signatures wins TGA greenlight for flu test device – just before winter

Genetic Signatures (ASX:GSS) shares were down -1.45% to 68cps on Monday, even as the company reported a greenlight from the TGA to sell its flu test devices on the market. At the same time, the Health Care sector is up +1.27% – suggestin...

themarketonline.com.au GSS 2 months ago
ASX Health Winners February: Law of attrition applies but biotech is a long term game; Nyrada up 5x last month

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Stockhead GSS 4 months ago
Check Up: Big week in world of biotech after these 2 Nasdaq stocks announce breakthroughs

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

Stockhead GSS 4 months ago
FNArena Corporate Results Monitor – 26-02-2024

Welcome to the FNArena Corporate Results Monitor. Today's Reports: ((29M)) - 29Metals ((AX1)) - Accent Group ((AMA)) - AMA Group ((APA)) - APA Group ((LTM)) - Arcadium Lithium ((A1N)) - ARN Media ((ABB)) - Aussie Broadband ((ASB)) - Austa...

FNArena GSS 4 months ago
Check Up: Biden-Xi meeting could finally end opioids crisis in the US; and recent ASX biotech winners

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Stockhead GSS 8 months ago
Check Up: Why Goldman Sachs won’t change its ratings on 3 ASX stocks despite Ozempic-driven selloff

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Stockhead GSS 9 months ago
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Stockhead GSS 9 months ago
The Overnight Report: Headwinds A-Blowin’

World Overnight SPI Overnight 7046.00 – 24.00 – 0.34% S&P ASX 200 7038.20 – 38.30 – 0.54% S&P500 4273.53 – 63.91 – 1.47% Nasdaq Comp 13063.61 – 207.71 – 1.57% DJIA 33618.88 – 388.00 – 1.14% S&P500 VIX 18.94 + 2.04...

FNArena GSS 9 months ago
The Overnight Report: Picking Bottoms

World Overnight SPI Overnight 7111.00 – 7.00 – 0.10% S&P ASX 200 7076.50 + 7.70 0.11% S&P500 4337.44 + 17.38 0.40% Nasdaq Comp 13271.32 + 59.51 0.45% DJIA 34006.88 + 43.04 0.13% S&P500 VIX 16.90 – 0.30 – 1.74% US...

FNArena GSS 9 months ago
Australian Broker Call *Extra* Edition – Sep 25, 2023

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

FNArena GSS 9 months ago
Weekly Ratings, Targets, Forecast Changes – 22-09-23

By Rudi Filapek-Vandyck, Editor FNArena Guide: The FNArena database tabulates the views of eight major Australian and international stockbrokers: Citi, Bell Potter, Macquarie, Morgan Stanley, Morgans, Ord Minnett, Shaw and Partners and UBS....

FNArena GSS 9 months ago
2 ASX biotech shares Bell Potter just upgraded to buy

If you have a high tolerance for risk, then read on! That's because Bell Potter has just upgraded two ASX biotech shares to buy ratings this morning. Here's why the broker is feeling upbeat about these high-risk stocks: Genetic Signatures...

Motley Fool GSS 9 months ago
Australian Broker Call *Extra* Edition – Sep 18, 2023

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listedequities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArenahas now ad...

FNArena GSS 10 months ago
Check Up: What is the FDA emergency use authorisation, and which ASX stocks were given approval?

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead GSS 10 months ago
Genetic Signatures submits to FDA for clearance of GI parasite detection kit

Australian molecular diagnostics company Genetic Signatures has submitted an application to the US FDA for regulatory clearance to market its EasyScreen Gastrointestinal Parasite Detection Kit.

BiotechDispatch GSS 10 months ago
In Case You Missed It: Rare earths on the rise, and coal seam gas pilot spudded

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Stockhead GSS 10 months ago
ASX Health Stocks: Genetic Signatures jumps 20pc on FDA update, Proteomics reveals new patent in Japan

Genetic Signatures jumps on FDA 510(k) application Allegra says FDA has questions related to its 510(k) application Proteomics granted patent in Japan   Genetic Signatures jumps almost 20pc on FDA update There were a couple of FDA-related...

Stockhead GSS 10 months ago
ASX Today: Stocks to watch on Monday

Futures indicate the ASX200 will open slightly higher as a new trading week commences, driven by growing confidence that the US Federal Reserve will pause at its next rates meeting due to the increase in unemployment in the country. In A...

themarketherald.com.au GSS 10 months ago
ASX Biotech August Winners: Sector down despite CSL and Cochlear’s strong results, but don’t panic…

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Stockhead GSS 10 months ago
Check Up: Australian biotech sector continues to be a magnet for US investors

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Stockhead GSS 10 months ago
ASX Today: Stocks to watch on Friday

Futures predict the ASX will open lower to finish the week, triggered by tech shares losing momentum on Wall Street and leading the market to also close lower. A highly anticipated speech by the US Federal Reserve chairman on the state o...

themarketherald.com.au GSS 10 months ago
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money will go

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

Stockhead GSS 11 months ago
Genetic Signatures (ASX:GSS) – TechKnow Invest Roadshow, August 2023

  Dr John Melki – CEO and Director – Genetic Signatures (ASX:GSS) is transforming molecular diagnostics via streamlined sample processing methods linked to highly multiplexed real-time PCR screening assays.

ShareCafe GSS 11 months ago
ASX Biotech Winners in July: Down but far from out, here’s why biotechs could stage a comeback

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead GSS 11 months ago
What to know about the TechKnow Invest Roadshow

Whilst the prevalence of Artificial intelligence has boosted the US-tech sector, with the likes of Nvidia and C3.ai seeing their share prices increase by 219% and 265% respectively since the start of the year, Down Under, tech stock valuati...

ShareCafe GSS 11 months ago
Check Up: Brisbane based Vaxxas set to disrupt market with game-changing, needle-free vaccines

Brisbane-based biotech Vaxxas is working on needles-free vaccine The Nanopatch is said to be a “game changer” We look at the best and worst performing ASX biotechs over the past month   The world is anticipating a “game changer” as Brisba...

Stockhead GSS 1 year ago
ASX Health Stocks: Sub $50m market cap Austco nabs $7.4m contract, the biggest in its history

Austco Healthcare wins St Paul’s Hospital in Canada worth $7.4m Next Science announced a new CEO AVITA Medical and Genetic Signatures announce new CFOs   Digital health company Austco Healthcare (ASX:AHC) surged by as high as 30% this mor...

Stockhead GSS 1 year ago
The Ethical Investor: Why Starpharma and these ASX biotechs could stop the next infectious disease outbreak

The infectious diseases space is one area that could be interesting for ethical investors An ASX company that already has a product in the market is Starpharma Stockhead reached out to Starpharma CEO, Jackie Fairley   Throughout history,...

Stockhead GSS 1 year ago
Check Up: Here’s the handful of ASX small cap health stocks that actually pay dividends

Small cap health stocks are not known to pay dividends But there’s a handful of such stocks on the ASX that do pay dividends We look at the best and worst performing ASX biotechs over the past week   When we talk about dividend-paying hea...

Stockhead GSS 1 year ago
Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m quarterly sales

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Stockhead GSS 1 year ago
MoneyTalks: Zip share price could quadruple while Genetic Signatures to triple, say these brokers

GSS’s share price could almost triple, according to Taylor Collison Taylor also believes Good Drinks could outperform Shaw and Partners says it has a target price on Zip that’s 4x current share price   Genetic Signatures to nearly triple...

Stockhead GSS 1 year ago
Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food, citing safety reasons CBD products have grown exponentially in the marketplace We take a look at what it all means for the cannabis industry   The US FDA announced last week that:...

Stockhead GSS 1 year ago
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past...

Stockhead GSS 1 year ago
The A to Z of Dr Boreham’s Crucible in 2022

The long and short of 2022 is that it was a frustrating period for the Australian biotech sector but one with its fair share of rewards as the sector’s exponents furthered worthy drugs, diagnostics, devices and doodahs. For the sixth year,...

Stockhead GSS 1 year ago
Webinar Recap – T92, GSS, ORR & SPT

ShareCafeWebinar Recap – T92, GSS, ORR & SPT Catch up on the full webinar with presentations from Terra Uranium (ASX: T92), Genetic Signatures (ASX: GSS), OrecORP (ASX: ORR) & Splitit (ASX: SPT) Webinar Recap – T92, GSS, ORR &...

ShareCafe GSS 1 year ago